更新于：2024-11-01

Malignant Gastric Gastrointestinal Stromal Tumor

恶性胃肠道间质瘤

更新于：2024-11-01

基本信息

别名

Gastric Malignant Gastrointestinal Stromal Tumor、Malignant Gastric Gastrointestinal Stromal Tumor

简介

A gastrointestinal stromal tumor arising from the stomach. It is characterized by large size (diameter greater than 10 cm) or more than 5 mitotic figures per 50 high power fields.

关联

项与恶性胃肠道间质瘤相关的药物

Sunitinib Malate

苹果酸舒尼替尼

靶点

PDGFR x RTK x VEGFR

作用机制

PDGFR拮抗剂 [+2]

在研机构

Pfizer Japan, Inc. [+4]

原研机构

Pfizer Inc.

在研适应症

恶性胃肠道间质瘤 [+12]

非在研适应症

肾上腺皮质癌 [+76]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2006-01-26

Imatinib mesylate

甲磺酸伊马替尼

靶点

ABL x Bcr-Abl x PDGFR x c-Kit

作用机制

ABL 抑制剂 [+3]

在研机构

National Cancer Institute [+11]

原研机构

Novartis Pharma AG

在研适应症

转移性胃肠道间质瘤 [+28]

非在研适应症

腹部肿瘤 [+169]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2001-05-10

Ziftomenib

靶点

MLL1 x menin

作用机制

MLL1抑制剂 [+2]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

项与恶性胃肠道间质瘤相关的临床试验

NCT06655246 / Not yet recruiting临床1期

A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.

开始日期2025-01-01

申办/合作机构

Kura Oncology, Inc.

CTR20230186 / CompletedN/A

甲磺酸伊马替尼片随机、开放、两制剂、两周期、两序列交叉、单次给药（0.1 g）、餐后状态下健康人体生物等效性试验

主要目的：以浙江麒正药业有限公司提供的甲磺酸伊马替尼片为受试制剂，按生物等效性试验的有关规定，与持证商 Novartis Pharma Schweiz AG的甲磺酸伊马替尼片（商品名：格列卫®，参比制剂）对比在健康人体内的吸收速度及吸收程度，考察两制剂的人体生物等效性。次要目的：观察受试制剂甲磺酸伊马替尼片和参比制剂甲磺酸伊马替尼片（格列卫®）在健康受试者中的安全性。

开始日期2023-02-14

申办/合作机构

浙江麒正药业有限公司

ChiCTR2200062796 / SuspendedN/AIIT

A single-center study comparing the safety and efficacy of endoscopic versus laparoscopic resection of gastrointestinal stromal tumors >= 3cm in diameter

开始日期2022-08-19

申办/合作机构

Taizhou Hospital of Zhejiang Province

100 项与恶性胃肠道间质瘤相关的临床结果

登录后查看更多信息

100 项与恶性胃肠道间质瘤相关的转化医学

登录后查看更多信息

0 项与恶性胃肠道间质瘤相关的专利（医药）

登录后查看更多信息

311

项与恶性胃肠道间质瘤相关的文献（医药）

2024-09-01·International Journal of Surgery Case Reports

Minimally invasive resection of gastric GIST tumor by trans-gastric approach: A case report of a novel technique

Article

作者: Omouri, Adel ; Hamed, Sami ; Kansoun, Alaa

INTRODUCTION AND IMPORTANCEGIST (Gastro Intestinal Stromal Tumor) treatment is surgical however surgical resection, especially for gGIST (gastric GIST), may be challenging due to location of tumor and the possible sequelae post resection.CASE PRESENTATIONWe present a case of 66-year-old female presented for the management of gGIST. We opted for transgastric resection assisted by robot. The resection was with free surgical margins for a 4 cm GIST tumor low in grade.CLINICAL DISCUSSIONClassical wedge resection of gastric tumors poses post-operative complications especially if the tumor is located near the cardia or pylorus. Various minimally invasive techniques were described aiming to avoid post-operative complications as in stenosis and gastric reflux.CONCLUSIONMinimally invasive transgastric resection of gGIST tumor seems to be worth of attention for it can prevent stenosis, hemorrhage and can preserve gastric tissue. Further studies need to be involved to endorse this technique.

2024-07-01·Hepatobiliary & Pancreatic Diseases International

Left hepatic marginal hemangioma with features resembling gastric stromal tumor

Letter

作者: Gao, Tian-Zhe ; Si, Yong-Qiang ; Wu, Xing-Nan ; Liu, Xiao-Sun ; Xu, Jia-Ren

2024-04-12·Alternative therapies in health and medicine

Diagnostic Value of Transabdominal Ultrasonography in Gastrointestinal Malignant Tumors.

Article

作者: Zheng, Jing ; Gao, Yan-Bing ; Tang, Li-Wei ; Dong, Jing-Yun

ObjectiveTo explore the application value of transabdominal ultrasonography in the diagnosis of gastrointestinal malignant tumors.MethodsThis study retrospectively analyzed the transabdominal ultrasound imaging data of 284 patients with gastrointestinal tumors admitted to our hospital from April 2019 to March 2022 and assessed the accuracy of transabdominal ultrasound in diagnosing different types of gastrointestinal tumor diseases. The diagnostic accuracy of transabdominal ultrasonography for TNM staging of gastrointestinal malignancies was calculated.ResultsThe sensitivity and specificity of transabdominal ultrasonography in the diagnosis of gastric cancer were (82.40% and 83.72%, respectively), colon cancer (77.78% and 88.35%, respectively), gastric stromal tumor (95.45% and 93.65%, respectively), gastric lymphoma (72.22% and 94.66%, respectively), colorectal lymphoma (80.00% and 95.42%, respectively), gastric mucosal hypertrophy (85.71% and 96.69%, respectively), and pyloric hypertrophy (92.59% and 97.79%, respectively). Among the 284 patients included, 152 patients had malignant tumors, including 34 patients with stage I, 30 patients with stage II, 51 patients with stage III, and 37 patients with stage IV. The accuracy of transabdominal ultrasonography for TNM staging of gastrointestinal malignancies was 85.53% (130/152).ConclusionTransabdominal ultrasonography shows promise as a diagnostic tool for gastrointestinal malignant tumors; however, it is recommended to be used in conjunction with other detection methods such as fibrous gastrointestinal tract examination to minimize the risk of missed diagnoses and misdiagnoses. The study highlights the potential of transabdominal ultrasonography as a non-invasive and accessible diagnostic method for gastrointestinal malignancies. Further research and advancements in imaging technologies are crucial for enhancing diagnostic capabilities and improving patient outcomes in the future.